Mabloc

Mabloc is a private, AI-native biotech founded in 2018 and based in San Diego, operating at the intersection of machine learning and therapeutic antibody development. The company's core asset is its BRAID™ platform, which uses AI to analyze vast libraries of antibody sequences, predict optimal candidates, and streamline the path from discovery to clinical trials. Mabloc appears to be in a pre-clinical, platform-validation stage, partnering with other drug developers while potentially advancing its own pipeline. Its approach targets the critical industry bottleneck of slow, costly traditional antibody discovery, particularly against rapidly evolving pathogens.

BRAID™: A generative AI platform that analyzes hundreds of thousands of antibody sequences to predict and optimize candidates for binding, specificity, and developability. It aims to identify rare 'super antibodies,' account for pathogen evolution, and drastically shorten the timeline from discovery to clinical candidate validation.

Mabloc competes in the rapidly growing field of AI-driven drug discovery, facing competitors like Absci (which integrates AI with wet-lab validation), Generate Biomedicines (generative biology), and Recursion (phenomics). It also competes with traditional antibody discovery CROs and large pharma internal AI efforts. Differentiation hinges on the unique capabilities and proven output of the BRAID™ platform.